Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110

Open Access

Peer-reviewed

Research Article

Wibke Deisting,

Affiliation Amgen Research (Munich) GmbH, Munich, Germany
⨯
Tobias Raum,

Affiliation Amgen Research (Munich) GmbH, Munich, Germany
⨯
Peter Kufer,

Affiliation Amgen Research (Munich) GmbH, Munich, Germany
⨯
Patrick A. Baeuerle,

Affiliation MPM Capital, Cambridge, Massachusetts, United States of America
⨯
Markus Münz

* E-mail: mmuenz@amgen.com

Affiliation Amgen Research (Munich) GmbH, Munich, Germany
⨯

Reader Comments (0)

T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
CHO cells
Is the Subject Area "CHO cells" applicable to this article?

Thanks for your feedback.
Transfection
Is the Subject Area "Transfection" applicable to this article?

Thanks for your feedback.
Adenosine
Is the Subject Area "Adenosine" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
Computer software
Is the Subject Area "Computer software" applicable to this article?

Thanks for your feedback.
Immune evasion
Is the Subject Area "Immune evasion" applicable to this article?

Thanks for your feedback.